Anxiety
Drug research and approvals for anxiety: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 1,218 studies of anxiety are recruiting on ClinicalTrials.gov, Health Canada has authorized 12 drug trials for it since 2013, and the EU has 9 authorised medicines for it.
- Recruiting worldwide: 1,218
- Trials authorized in Canada: 12
- FDA orphan approvals: 0
- EU medicines: 9
- From There Towards Now; Intervention for Jewish and Indonesian Post-war GenerationsNCT07950800 · Not applicable · Arkin · starts Apr 1, 2025
- Effects of the Music Care Therapeutic Music Intervention on Well-Being and Anxiety in Hospitalized PatientsNCT07949357 · Not applicable · Hospital St. Joseph, Marseille, France · starts Nov 3, 2026
- Mini-RISK in Agder: A Cluster Randomized Controlled Trial of a Low-Threshold School-Based Program for Anxious Students…NCT07946510 · Not applicable · Sorlandet Hospital HF · starts Nov 20, 2026
- A Prospective, Multicenter, Observational Study to Evaluate the Efficacy and Safety of Dexmedetomidine Hydrochloride…NCT07944846 · Not reported · Tongji Hospital · starts Jun 18, 2026
- Exploring Trauma Plus (ET+)NCT07945639 · Not applicable · Envisioning Justice Solutions, Inc · starts Apr 1, 2026
- Exploring the Interplay Between Maternal Stress, Human Milk, and Epigenetic Changes in Preterm Infant's NeurodevelopmentNCT07943130 · Not reported · Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · starts Aug 25, 2026
- Study of Anxiety Free Experiences at the DentistNCT07931131 · Not applicable · University of Texas Rio Grande Valley · starts Nov 1, 2026
- The Effects of Social Media Restriction on Social Anxiety, Fear of Missing Out, and Health-related Quality of LifeNCT07929688 · Not applicable · University of Lausanne · starts Nov 9, 2026
- The Effects of Laughter Yoga and Progressive Muscle Relaxation Exercises on Pregnancy Symptoms and Pregnancy-Related…NCT07927426 · Not applicable · Selcuk University · starts Nov 1, 2026
Approved 20
- AlprazolamGABA-A receptor; anion channel positive allosteric modulator
- LorazepamGABA-A receptor; anion channel positive allosteric modulator
- EscitalopramSerotonin transporter inhibitor
- DiazepamGABA-A receptor; anion channel positive allosteric modulator
- HydroxyzineHistamine H1 receptor antagonist
- BuspironeSerotonin 1a (5-HT1a) receptor partial agonist
- ClobazamGABA-A receptor; anion channel positive allosteric modulator
- OxazepamGABA-A receptor; anion channel positive allosteric modulator
- BromazepamGABA receptor alpha-2 subunit positive allosteric modulator
- ChlordiazepoxideGABA-A receptor; anion channel positive allosteric modulator
- Clorazepic acidGABA-A receptor; anion channel positive allosteric modulator
- ProchlorperazineDopamine D2 receptor antagonist
- TrifluoperazineSerotonin 2a (5-HT2a) receptor antagonist
- MeprobamateGABA-A receptor; anion channel agonist
- PrazepamGABA-A receptor; anion channel positive allosteric modulator
- HalazepamGABA-A receptor; anion channel positive allosteric modulator
- Mebutamate
- ClotiazepamGABA-A receptor; anion channel positive allosteric modulator
- Ketazolam
- Medazepam
Phase 3 12 of 100
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- ParoxetineSerotonin transporter inhibitor
- DuloxetineSerotonin transporter inhibitor
- VenlafaxineSerotonin transporter inhibitor
- AmibegronBeta-3 adrenergic receptor agonist
- MelatoninMelatonin receptor agonist
- RisperidoneSerotonin 2a (5-HT2a) receptor antagonist
- QuetiapineSerotonin 2a (5-HT2a) receptor antagonist
- SertralineSerotonin transporter inhibitor
- DexmedetomidineAdrenergic receptor alpha-2 agonist
- TiagabineGABA transporter 1 inhibitor
- PregabalinVoltage-gated calcium channel modulator
Phase 2 12 of 30
- CannabidiolCannabinoid CB1 receptor negative allosteric modulator
- AZD7325GABA receptor alpha-2 subunit positive allosteric modulator
- Lysergide
- ButorphanolMu opioid receptor partial agonist
- MidomafetamineSodium-dependent dopamine transporter releasing agent
- MK-0777
- AcetaminophenCyclooxygenase inhibitor
- ClonidineAdrenergic receptor alpha-2 agonist
- PropranololBeta-1 adrenergic receptor antagonist
- LidocaineSodium channel alpha subunit blocker
- GemcitabineRibonucleoside-diphosphate reductase RR1 inhibitor
- NelivaptanVasopressin V1b receptor antagonist
Phase 1 or earlier 12 of 16
- FlumazenilGABA-A receptor; anion channel allosteric antagonist
- MifepristoneGlucocorticoid receptor antagonist
- CycloserineD-alanylalanine synthetase inhibitor
- PrazosinAdrenergic receptor alpha-1 antagonist
- TC-2216Neuronal acetylcholine receptor; alpha4/beta2 antagonist
- AZD6280GABA receptor alpha-2 subunit positive allosteric modulator
- SRX246Vasopressin V1a receptor antagonist
- AticaprantKappa opioid receptor antagonist
- PsilocybinSerotonin 2a (5-HT2a) receptor agonist
- Niacin
- Water
- Pivagabine
How its trials ended
2,985 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 494 whose ending is known, 57% met their primary endpoint, 8% missed it and 35% stopped early.
- Completed, result not reported1,46149%
- Ongoing68723%
- Status unknown34311%
- Met its primary endpoint2829%
- Stopped: other or unclear1134%
- Missed its primary endpoint381%
- Stopped: enrollment or feasibility311%
- Stopped: sponsor or business decision11<1%
- Stopped: funding11<1%
- Stopped: lack of efficacy6<1%
- Stopped: safety2<1%
| Jul 23, 2024 | Treatment with l-methylfolate for treatment-resistant generalized anxiety disorder: a pilot studyMethylfolate | Queens University | Pending |
| Apr 24, 2024 | Psilocybin-assisted existential, attachment and relational (PEARL) therapy for caregivers of patients with advanced cancer: a phase II open-label trialPsilocybin | University Health Network | Ongoing |
| Jan 18, 2024 | A phase 2a, placebo-controlled randomized, double-blind trial to evaluate the safety, tolerability, and preliminary efficacy of psilocybin oral solution in…Psilocybin | Dr. Claudio Soares | Ongoing |
| Jan 12, 2023 | A 2-part, phase 2a, randomized, double-blind trial to evaluate the safety, tolerability, and efficacy of psilocybin oral solution in adults with generalized…Psilocybin | Diamond Therapeutics | Pending |
| Aug 3, 2022 | Psilocybin assisted therapy for anxiety and mood disorders: a transdiagnostic open label clinical trial for improving well-being (pam-well)Psilocybin | Brain and Cognition Discovery Foundation | Closed |
| Mar 16, 2021 | A randomized placebo-controlled trial of sertraline vs. placebo in the treatment of anxiety in children and adolescents with neurodevelopmental disordersSertraline | Dr Evdokia Anagnostou | Ongoing |
| Jul 24, 2019 | Cannabidiol for the treatment of anxiety disorders: an 8-week pilot studyTN-C200M2 (cannabidiol) / TN-TC11M2 (cannabidiol - DELTA-9-tetrahydrocannabinol) | Macanxiety Research Centre | Pending |
| Jul 4, 2019 | Chi-902 (cannabis oil) for treatment of social anxiety disorder - a phase IIb randomized double-blind placebo-controlled clinical trialCHI-902 (DELTA-9-tetrahydrocannabinol - cannabidiol) | Canopy Health Innovations Inc | Closed |
| Jan 28, 2019 | The safety, efficacy and tolerability of microbial ecosystem therapeutic-2 in people with majoy depression and/or generalized anxiety disorderMET-2 (microbial ecosystem therapeutic-2) | Nubiyota | Pending |
| Feb 2, 2018 | Open label 8-week study of prazosin use in adults with anxiety disordersPrazosin | University of Manitoba | Ongoing |
| Aug 28, 2015 | Pregabalin AccordPregabalin · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Aug 20, 2015 | Duloxetine ZentivaDuloxetine · generic | Zentiva k.s. | EMA ↗ |
| Jul 17, 2015 | Pregabalin ZentivaPregabalin · generic | Zentiva k.s. | EMA ↗ |
| Jun 24, 2015 | Pregabalin Viatris (previously Pregabalin Mylan)Pregabalin · generic | Viatris Limited | EMA ↗ |
| Jun 19, 2015 | Duloxetine Viatris (previously Duloxetine Mylan)Duloxetine · generic | Viatris Limited | EMA ↗ |
| Jun 19, 2015 | Pregabalin SandozPregabalin · generic | Sandoz GmbH | EMA ↗ |
| Dec 8, 2014 | Duloxetine LillyDuloxetine | Eli Lilly Nederland B.V. | EMA ↗ |
| Apr 10, 2014 | Pregabalin Viatris Pharma (previously Pregabalin Pfizer)Pregabalin | Viatris Healthcare Limited | EMA ↗ |
| Dec 17, 2004 | CymbaltaDuloxetine | Eli Lilly Nederland B.V. | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA